Veliparib (ABT-888)

For research use only. Not for use in humans.

目录号：S1004 别名： NSC 737664 中文名称：维利帕尼

CAS No. 912444-00-9

Veliparib (ABT-888, NSC 737664)是一种有效的PARP1和PARP2抑制剂，无细胞试验中K_i分别为5.2 nM和2.9 nM，对SIRT2没有活性。Veliparib 可增加自噬和凋亡。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1277.12	现货
10mg	RMB 973.01	现货
25mg	RMB 1859.13	现货
50mg	RMB 3010.72	现货
200mg	RMB 8108.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Veliparib (ABT-888)发表文献189篇：

Nature, 2019, 572(7768):254-259

PubMed: 31316209 ( click the link to review the publication )

Cancer Cell, 2019, 35(6):851-867

PubMed: 31185210 ( click the link to review the publication )

Nature, 2018, 559(7713):279-284

PubMed: 29950726 ( click the link to review the publication )

Nature, 2018, 559(7713):285-289

PubMed: 29973717 ( click the link to review the publication )

Cancer Discov, 2018, 8(8):988-1005

PubMed: 29880585 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nature, 2017, 5;541(7635):87-91.

PubMed: 28002403 ( click the link to review the publication )

Cell, 2016, 167(1):233-247

PubMed: 27662091 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Sci Transl Med, 2021, 13(592)eabc7211

PubMed: 33952676 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00739-5

PubMed: 34555355 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00367-1

PubMed: 34102105 ( click the link to review the publication )

Sci Adv, 2021, 7(11)eabe9446

PubMed: 33712463 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab771

PubMed: 34508355 ( click the link to review the publication )

Neuro Oncol, 2021, 23(6):920-931

PubMed: 33433610 ( click the link to review the publication )

EMBO Rep, 2021, 22(5):e51851

PubMed: 33932076 ( click the link to review the publication )

Cell Rep, 2021, 36(4):109429

PubMed: 34320344 ( click the link to review the publication )

Cells, 2021, 10(6)1289

PubMed: 34067418 ( click the link to review the publication )

Mol Neurobiol, 2021, 10.1007/s12035-021-02371-4

PubMed: 33788167 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(8):2099-2111

PubMed: 34131409 ( click the link to review the publication )

Mol Cancer Res, 2021, 10.1158/1541-7786.MCR-20-0791

PubMed: 33863812 ( click the link to review the publication )

J Pharmacol Exp Ther, 2021, 377(3):385-397

PubMed: 33820831 ( click the link to review the publication )

Cell Signal, 2021, S0898-6568(21)00195-9

PubMed: 34363951 ( click the link to review the publication )

Mol Med Rep, 2021, 23(1)40

PubMed: 33179075 ( click the link to review the publication )
bioRxiv, 2021, 10.1101/2020.10.18.333070

PubMed: None ( click the link to review the publication )

Int J Mol Sci, 2021, 22(4)1638

PubMed: 33562002 ( click the link to review the publication )

Cancer Lett, 2021, S0304-3835(21)00092-6

PubMed: 33652085 ( click the link to review the publication )

Cell Death Differ, 2021, 10.1038/s41418-020-00733-4

PubMed: 33531658 ( click the link to review the publication )

Nat Commun, 2021, 12(1):736

PubMed: 33531508 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30902-3

PubMed: 33412112 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30898-4

PubMed: 33333017 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2174

PubMed: 32358582 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Sci Adv, 2020, 22;6(17):eaaz3221

PubMed: 32494639 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 33(5):108347

PubMed: 33147465 ( click the link to review the publication )

Aging Cell, 2020, 19(6):e13163

PubMed: 32475059 ( click the link to review the publication )

Elife, 2020, 9e60637

PubMed: 32844745 ( click the link to review the publication )

Oncogene, 2020, 39(14):2905-2920

PubMed: 32029902 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

DNA Repair (Amst), 2020, 85:102749

PubMed: 31790865 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30595-5

PubMed: 33285109 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15086

PubMed: 32934320 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3836

PubMed: 32123273 ( click the link to review the publication )

Front Pharmacol, 2020, 11:610205

PubMed: 33519476 ( click the link to review the publication )

Biochemistry, 2020, 10.1021/acs.biochem.0c00256

PubMed: 32357296 ( click the link to review the publication )
SLAS Discov, 2020, 25(3):241-252

PubMed: 31855104 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6118

PubMed: 33257658 ( click the link to review the publication )

Mol Cell, 2020, 80(5):862-875.e6

PubMed: 33275888 ( click the link to review the publication )

Sci Rep, 2020, 10(1):9775

PubMed: 32555249 ( click the link to review the publication )

Dis Markers, 2020, 2020:8259820

PubMed: 32714467 ( click the link to review the publication )

Sci Signal, 2020, 13(645):eaba8091

PubMed: 32817374 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107884

PubMed: 32668240 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa590

PubMed: 32667640 ( click the link to review the publication )

Transl Oncol, 2020, 13(11):100834

PubMed: 32688248 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3391

PubMed: 32636369 ( click the link to review the publication )

Oncotarget, 2020, 11(23):2141-2159

PubMed: 32577161 ( click the link to review the publication )

Oncol Lett, 2020, 19(4):2629-2638

PubMed: 32218813 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 10.1016/j.ijrobp.2020.01.030

PubMed: 32036006 ( click the link to review the publication )

Nat Microbiol, 2019, 4(11):1872-1884

PubMed: 30988430 ( click the link to review the publication )

Mol Cell, 2019, 75(1):117-130

PubMed: 31101499 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4632

PubMed: 31604914 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(12):1223-1231

PubMed: 31659317 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4196

PubMed: 31519936 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5654

PubMed: 31827085 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2549

PubMed: 31852834 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(10):2015-2030

PubMed: 30725116 ( click the link to review the publication )
Cancers (Basel), 2019, 12(1)

PubMed: 31861350 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):4

PubMed: 30616689 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 17:701-713

PubMed: 31422287 ( click the link to review the publication )

Stem Cells, 2019, 37(1):42-53

PubMed: 30353615 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Sci Rep, 2019, 9(1):3309

PubMed: 30824778 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.10.141

PubMed: 31679697 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30401677 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830864 ( click the link to review the publication )

Acta Neuropathol Commun, 2018, 6(1):84

PubMed: 30157956 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

Nat Commun, 2018, 9(1):967

PubMed: 29511213 ( click the link to review the publication )

Nat Commun, 2018, 9(1):176

PubMed: 29330466 ( click the link to review the publication )

EMBO J, 2018, 37(14)

PubMed: 29875130 ( click the link to review the publication )

EMBO Rep, 2018, 19(10):e46783

PubMed: 30291165 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30088474 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(12):1547-1553

PubMed: 30344052 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

J Immunol, 2018,

PubMed: 29445007 ( click the link to review the publication )
J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 500(2):333-338

PubMed: 29654761 ( click the link to review the publication )

SLAS Discov, 2018, 23(6):545-553

PubMed: 29676938 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(2):804-822

PubMed: 29216372 ( click the link to review the publication )

DNA Repair (Amst), 2018, 64:1-9

PubMed: 29459202 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2892-2901

PubMed: 28958991 ( click the link to review the publication )

Invest New Drugs, 2017, 35(3):251-259

PubMed: 28111726 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68707-68720

PubMed: 28978150 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103931-103951

PubMed: 29262611 ( click the link to review the publication )

EMBO Rep, 2016, 17(11):1609-1623

PubMed: 27596623 ( click the link to review the publication )

Cell Rep, 2016, 17(9):2367-2381

PubMed: 27880910 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2302

PubMed: 27441654 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3087-3096

PubMed: 27638859 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(12):3027-3039

PubMed: 27686254 ( click the link to review the publication )

Neuropharmacology, 2016, 110(Pt A):287-296

PubMed: 27497606 ( click the link to review the publication )

Cancer Gene Ther, 2016, 23(10):348-354

PubMed: 27632933 ( click the link to review the publication )

Mol Pharmacol, 2016, 90(2):65-79

PubMed: 27193581 ( click the link to review the publication )
Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Toxicol Lett, 2016, 244:56-71

PubMed: 26383629 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155711

PubMed: 27196668 ( click the link to review the publication )

Chem Biol Drug Des, 2016, 87(3):478-82

PubMed: 26518726 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Oncotarget, 2016, 7(29):44950-44965

PubMed: 27391435 ( click the link to review the publication )

Oncotarget, 2016, 7(20):28765-82

PubMed: 27144834 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(3):1161-78

PubMed: 26578593 ( click the link to review the publication )

Mutat Res, 2016, 790:31-40

PubMed: 27427773 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7701-14

PubMed: 26713604 ( click the link to review the publication )

Sci Adv, 2015, 1:e1400203

PubMed: ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26374986 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2818-30

PubMed: 26438158 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11):2560-8

PubMed: 26351319 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Carcinogenesis, 2015, 36(8):832-40

PubMed: 26025911 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(12):3506-17

PubMed: 25788520 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

J Nutr Biochem, 2015, 26(12):1442-7

PubMed: 26350251 ( click the link to review the publication )

J Transl Med, 2015, 13:74

PubMed: 25886061 ( click the link to review the publication )

J Transl Med, 2015, 13(1):427

PubMed: 25779137 ( click the link to review the publication )

Biochem J, 2015, 469(2):189-98

PubMed: 25940138 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):262-8

PubMed: 25975349 ( click the link to review the publication )
Cancer Discov, 2015, 5(7):752-67

PubMed: 26069190 ( click the link to review the publication )

Metabolomics, 2015, 11(6):1779-1791

PubMed: 26478723 ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 458(3):520-4

PubMed: 25677620 ( click the link to review the publication )

J Breast Cancer, 2015, 18(4):329-38

PubMed: 26770239 ( click the link to review the publication )

J Vet Emerg Crit Care (San Antonio), 2015, 25(4):528-37

PubMed: 26040949 ( click the link to review the publication )

Sci Adv, 2015, 1(3):e1400203

PubMed: 26601161 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(10):2703-13

PubMed: 24647572 ( click the link to review the publication )

J Cell Biol, 2014, 206(4):493-507

PubMed: 25113031 ( click the link to review the publication )

Cell Rep, 2014, 9(3):829-41

PubMed: 25437539 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Oncogene, 2014, 8.559

PubMed: 24769898 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Oral Oncol, 2014, S1368-8375(14)00163-8

PubMed: 25017803 ( click the link to review the publication )

FEBS J, 2014, 281(16):3625-41

PubMed: 24953096 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(8):1128-39

PubMed: 24770870 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

frontiers in genetic, 2014, 5:116-126

PubMed: 24904630 ( click the link to review the publication )

J Biol Chem, 2014, 289(13):9247-53

PubMed: 24554720 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

Transl Oncol, 2014, 10.1016/j.tranon.2014.04.003

PubMed: 24836647 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101844

PubMed: 25025768 ( click the link to review the publication )
Asian Pac J Trop Med, 2014, 7(6):468-72

PubMed: 25066396 ( click the link to review the publication )

Asian Pac J Trop Med, 2014, 468-472

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3115-29

PubMed: 24833108 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Cancer Res, 2013, 73(12):3683-91

PubMed: 23548269 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

J Antimicrob Chemother, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

J Viral Hepat, 2013, 20(9):658-65

PubMed: 23910651 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55883

PubMed: 23405229 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7344-55

PubMed: 23761435 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(21):5878-87

PubMed: 22966016 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

Mol Pharmacol, 2012, 82(4):767-76

PubMed: 22833573 ( click the link to review the publication )

Nucl Med Commun, 2012, 32(11):1046-51

PubMed: 21956491 ( click the link to review the publication )

Cancer Res, 2011, 71(14):4944-54

PubMed: 21613406 ( click the link to review the publication )

PLoS One, 2011, 6(12):e28862

PubMed: 22194930 ( click the link to review the publication )

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述

特性

ABT-888增强常见癌症疗法的效果，比如放射疗法和烷基化剂。

靶点

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
2.9 nM(Ki)	5.2 nM(Ki)

体外研究

ABT-888有效抑制PARP，作用于PARP-1和PARP-2时K_i值分别为5.2和2.9 nM。ABT-888降低肺癌H460细胞中克隆基因的存活率，且抑制DNA修复。^[1]ABT-888抑制C41细胞，EC50为2 nM。^[2] ABT-888和放射物联用减少肿瘤血管的形成。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
C41	MVXLbY5ie2ViQYPzZZk>		M4TJTVMxKG2rbh?=		Mn7oTY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6OEe2NEc,OTl6OEi3OlA9N2F-
Jurkat	NWnaWm9xU2mwYYPlJGF{e2G7		MY[5OkBp	M1XHTmROW09?	MoLCTY5pcWKrdHnvckBw\iCSQWLQNUBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gZ4VtdCC4aXHibYxqfHlid3n0bEBGSzVyIH;mJFMh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEG5PUc,OjN6NUCxPVk9N2F-
Capan1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYe3NkBp	M2rKNWROW09?	Mn;URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB\|OT63JO69VQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7OEO4N{c,OjR\|OUizPFM9N2F-
DT40	MWXDfZRwfG:6aXOgRZN{[Xl?		MkfzO\|IhcA>?	M3eybWROW09?	NWrDbmdlS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>?	M{LSXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUKyOVg4Lz5{NEmyNlU5PzxxYU6=
ML-1	NX;PUG1sSXCxcITveIlkKEG\|c3H5	MWCyMlUh\|ryP	NISy[pMzPCCq	MXjEUXNQ	NI\sbXZUgW6ncnfpd5Rq[2GubImg[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXNiaX6gUWwuOSClZXzsdy=>	Mm\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUWxN\|UoRjJ2OEm1NVM2RC:jPh?=
HCT-116	MoW1T4lv[XOnIFHzd4F6	NWnQSldKOC53IN88US=>	NFPEXnEzPCCq		NYX6e3ZmWEGUUDDhZ5Rqfmm2eTDk[YNz\WG\|ZYO=	M1H0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW0NlE{Lz5{M{C1OFIyOzxxYU6=
UM-SCC1	MnPYR5l1d3SxeHnjJGF{e2G7	NGnOWpAyOCEQvF2=	NWH4N4dzOjRiaB?=		NVnrSIhwWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk>	NXfyNGd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NVI3OjBpPkKxPVEzPjJyPD;hQi=>
FaDu	MkDYR5l1d3SxeHnjJGF{e2G7	MUixNEDPxE1?	MXyyOEBp		MVvS[YR2[2W\|IITo[UBk\WyuII\pZYJqdGm2eR?=	MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MUK2NlAoRjJzOUGyOlIxRC:jPh?=
PC-3	NIDEN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;KNVAh\|ryP			NEH4[ZhKdmS3Y3XzJIEhe2mpbnnmbYNidnRiaX7obYJqfGmxbjDpckBkd2yxbomg[o9zdWG2aX;uxsA>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MUmxNkc,OjF3N{G5NVI9N2F-
C41	NGj2N2NHfW6ldHnvckBie3OjeR?=				NIX5b5VKdmirYnn0bY9vKG:oIGDBVnAyKGmwIHj1cYFvKEN2MTDj[YxteyxiRVO1NEA:KDBwMECyJO69VS5?	Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzNEO1OlkoRjF7MUSzOVY6RC:jPh?=
LoVo	NX3hT3hZTnWwY4Tpc44h[XO\|YYm=		MYGzNEBucW6\|		M2jJZWlvcGmkaYTpc44hd2ZiUFHSVEBqdiCqdX3hckBNd1[xIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheG:ueTjBSHAqNXKrYn;z[UBxd2y7bXXybZpifGmxbjDmc5IhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFXDOVAhRSByLkCwOVk1KM7:TT6=	M1\C[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO\|E4Lz5{Nk[1NlcyPzxxYU6=
LoVo	MV;GeY5kfGmxbjDhd5NigQ>?		MXSzNEBucW6\|		NXq2emIxUW6qaXLpeIlwdiCxZjDQRXJRKGmwIHj1cYFvKEyxVn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyb3z5LGFFWClvcnnic5NmKHCxbInt[ZJqgmG2aX;uJIZweiB\|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygSWM2OCB;IECuNFA2QTRizszNMi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
LoVo	M1[3ZWZ2dmO2aX;uJIF{e2G7		MljuN\|AhdWmwcx?=		M4fYNmlvcGmkaYTpc44hd2ZiUFHSVEBqdiCqdX3hckBNd1[xIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheG:ueTjBSHAqNXKrYn;z[UBxd2y7bXXybZpifGmxbjDmc5IhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFXDOVAhRSByLkCwOVk1KM7:TT6=	M1[3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO\|E4Lz5{Nk[1NlcyPzxxYU6=
VC8	NILzbWFEgXSxdH;4bYNqfHliYYPzZZk>		NELMNoI{KGSjeYO=		NGL2RpJEgXSxdH;4bYNqfHliYXfhbY5{fCCFaHnu[ZNmKGijbYP0[ZIhXkN6IHPlcIx{KGijcnLvdolv\yCEUlPBNkBl\W[rY3nlcpQh[W[2ZYKgN{Bl[Xm\|IHL5JGNEUzhiYYPzZZktKEOFNUCgQUAzNjN2NDFOwG0v	NGPoWmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOzOVIxPSd-MkmzN\|UzODV:L3G+
LoVo	M4L3XmN6fG:2b4jpZ4l1gSCjc4PhfS=>	MoPsNE41KHWP	Ml3tOUBl[Xm\|		M{\4VHBwfGWwdHnheIlwdiCxZjD0[Y1wgm:ub33p[IUucW6mdXPl[EBkgXSxdH;4bYNqfHliaX6gbJVu[W5iTH;Wc{Bk\WyuczDhd5Nme3OnZDDhd{B1\W2xen;sc41q\GViR1m1NEBifCByLkSgeW0h[W[2ZYKgOUBl[Xm\|IHL5JGNmdGy2aYTldk1IdG9iYYPzZZktKEeLNUCgQUA3NjJyMzFOwG0v	NFrh[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
A673	NVfYTFhqeUiWUzDhd5NigQ>?				M1vFcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NWm4W\|NIeUiWUzDhd5NigQ>?				M4WyWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NHrXRmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MlL1dWhVWyCjc4PhfS=>				MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	M4f5bZFJXFNiYYPzZZk>				MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	NHPOZ2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MkHYdWhVWyCjc4PhfS=>				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NIHaXoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	M{GwW5FJXFNiYYPzZZk>				NGHHXohyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NIi4clZyUFSVIHHzd4F6				NGLjWZhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
EoL-1-cell	MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7uTWM2OD1zLkC3PVgh\|ryP	MljKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
NCI-SNU-5	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHO2fJlKSzVyPUOuNVI5PDFizszN	NGj3SlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
BV-173	NF7PR\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTJTWM2OD13LkS1OFA6KM7:TR?=	NIrydIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
HCC1806	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTVwN{WxO\|Mh\|ryP	MmCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
COLO-680	M4nD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnSdVRFUUN3ME22MlIyPDB4IN88US=>	MoHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
HCC2218	M2DsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnCWlZKSzVyPUeuO\|k4ODRizszN	NXHpR3hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
SK-MEL-24	NGPNTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXP3V5BnUUN3ME23MlgyQTJ2IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
NCI-H720	NYP5U2lHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLTT3NKSzVyPUiuOFM3ODNizszN	NGmxNWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
KASUMI-1	NF7UdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmOzTWM2OD16Lki5NlY3KM7:TR?=	NEjLWJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
HAL-01	M1vRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHSTWM2OD17Lki4OlIh\|ryP	NIT0OGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
CAL-33	NYLJdlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPwb2szUUN3ME2xNE41OzRizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
SK-MEL-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzHTWM2OD1zMj60OlY{KM7:TR?=	NEG5Ooc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXi2dlB{UUN3ME2xNk41PzV{IN88US=>	M4f0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
KY821	M1zzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PnOmlEPTB;MUKuOFg2KM7:TR?=	MkXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
HEC-1	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfTTWM2OD1zMj65NVk3KM7:TR?=	Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
SK-NEP-1	M330ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTXTWM2OD1zMz6xOlYh\|ryP	NWrVWJpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
MN-60	M2r5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmm3TWM2OD1zMz61N\|g6KM7:TR?=	MoDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
DU-145	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIC4ZoZKSzVyPUGzMlkxPTNizszN	MnzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
EW-3	NX;vXHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn63TWM2OD1zND61OVY2KM7:TR?=	M4W5blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
OS-RC-2	NV3ScmV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXVdZhXUUN3ME2xOU46PTh7IN88US=>	M3H3SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
RPMI-8226	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXrTWM2OD1zNj6yNFQzKM7:TR?=	NW\jS2ZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
ChaGo-K-1	NXqxUINjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTF4LkWzNlUh\|ryP	M4HmdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
DEL	NGfEXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP5TWM2OD1zNj62O\|E4KM7:TR?=	NF;WUGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
GP5d	MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml2wTWM2OD1zNz6wOVMh\|ryP	NVjrdnVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
COLO-668	NXzjZoxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT5[FhVUUN3ME2xO{43Ojl2IN88US=>	MkXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
H9	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3uyNWlEPTB;MUiuNlg{OyEQvF2=	NGK3b3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
NKM-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzqfYxKSzVyPUG4MlUyOTlizszN	MoDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
KYSE-150	NWrLRWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPxdoFrUUN3ME2xPE46QTh4IN88US=>	M2jZS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
Daoy	MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LCS2lEPTB;MUmuOVY1QSEQvF2=	MnHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
ECC10	NELQU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVmxR4JQUUN3ME2yNE44PDV3IN88US=>	NITi[og9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
A388	NVzNS\|RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJzLkmwPVEh\|ryP	NHf3Opc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
MHH-NB-11	M3TEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HYWWlEPTB;MkOuNVM3OyEQvF2=	MmHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
HCC1937	MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;YenRuUUN3ME2yOE44PDZizszN	MkHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
TGBC11TKB	M3zoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PtbWlEPTB;MkWuOlg3OyEQvF2=	MkDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
CTV-1	NH7PUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEi0XWxKSzVyPUK1Mlg6PjlizszN	NETGWJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
NCI-H2029	M2[zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33DfWlEPTB;Mk[uOFI{QCEQvF2=	NGXCc\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
HLE	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\mb5JiUUN3ME2yO{4xPTRizszN	NXPoZYVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
NCI-H1693	M1LWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzlTWM2OD1{Nz6yPFk5KM7:TR?=	NH\hdFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
HCC70	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTXNJVKSzVyPUK3MlczPDZizszN	M{LKc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
BEN	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJ5Lkm1OlYh\|ryP	MlvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
LB771	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmj6TWM2OD1{OD64N\|c{KM7:TR?=	NVHoZnhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
697	NGqwNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\2cXFKSzVyPUK5MlAzOzVizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
LU-139	M3rLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLaS45wUUN3ME2yPU4{PzR6IN88US=>	M1nVRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
EW-13	M4j3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrJc4JKSzVyPUK5MlM5OTRizszN	M1PmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MOLT-13	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTJ7LkO4NVQh\|ryP	NHPWXXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
L-363	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTJ7LkS3PVgh\|ryP	M4TrSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
EM-2	Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDTe3VKSzVyPUK5MlQ6ODFizszN	NWLaVnZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
RS4-11	M{jwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vwR2lEPTB;M{CuOFI1OSEQvF2=	NHHrOnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
A2780	NUTVWnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDUU2FKSzVyPUOwMlc1PTdizszN	NGXERVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
KU812	NYrDfXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmL6TWM2OD1\|Mj6zOlQzKM7:TR?=	M17NZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
COLO-684	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\mU4pKSzVyPUOzMlM2QTlizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
MFE-280	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWixfXJuUUN3ME2zN{4{QDh7IN88US=>	M2q4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
KG-1	M1Tu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\rXVZ4UUN3ME2zN{43ODBzIN88US=>	MojPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
JVM-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTN3LkW4Olgh\|ryP	M1XCeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MV-4-11	NFjsVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXH6TppNUUN3ME2zOU45PDl7IN88US=>	M4\aTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
LAMA-84	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTN4LkezOFUh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
MOLT-16	M{\iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTaTWM2OD1\|Nj65OVIh\|ryP	M1znNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
H4	M2W4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTN5LkW2O{DPxE1?	MnmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
T47D	NFfRO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[wTWM2OD1\|Nz63NFE5KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
CAL-54	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PaZmlEPTB;M{euPVY3KM7:TR?=	NXLCcZR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
SW982	M3H2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTN6LkC5PVgh\|ryP	NELUeJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
IGROV-1	NWPyc\|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTN7LkOzNFQh\|ryP	NUexfmxTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
NB14	M1LCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHqSWNSUUN3ME20NE44ODNzIN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
HCC1187	NET2b3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M335[WlEPTB;NEGuNlc4OSEQvF2=	Ml;SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
SBC-1	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\5ZmxmUUN3ME20NU4{ODZ\|IN88US=>	M{G5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
KARPAS-45	M{jUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrUTVA6UUN3ME20NU41QDF6IN88US=>	M2PG[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MOLT-4	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfwOHZKSzVyPUSyMlI2OzhizszN	NELicIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
JVM-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vJNmlEPTB;NEKuPVIxPyEQvF2=	Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
A4-Fuk	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTR\|LkW2PVEh\|ryP	NYHMbo9ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
MDA-MB-361	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LNdGlEPTB;NEOuPFQyPCEQvF2=	MlLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
BALL-1	M3O3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X2c2lEPTB;NEOuPVU{OiEQvF2=	NIfkPFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
T98G	M1TaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzLeGJMUUN3ME20OE45PTF5IN88US=>	MoDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
Mo-T	NXjkVVRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHK5NHRKSzVyPUS1MlY{QDlizszN	NE[4PJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK\|5USU6JRWK8M4E,
MHH-PREB-1	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7jTWM2OD12NT63OVg2KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
ALL-PO	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjGblBKSzVyPUS3MlM4QTFizszN	MmLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
NCI-H510A	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHqPIRKSzVyPUS3MlkxOzRizszN	M4\SNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
ML-2	M3vifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlP4TWM2OD12OT63PFU3KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; PubMed: 22678161 Breast Cancer Res Treat Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment	22678161
Immunofluorescence	BRCA1; PubMed: 21917757 Int J Oncol Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion. HuR; PubMed: 28687616 Cancer Res Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.	21917757 28687616
Growth inhibition assay	Cell viability (melanoma cells); PubMed: 29956724 Int J Oncol Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (P<0.05; *P<0.01). Cell viability (TNBC cell lines); PubMed: 27880910 Cell Rep BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.	29956724 27880910

体内研究

ABT-888推迟NCI-H460 移植瘤模型的肿瘤生长。ABT-888在B16F10 和9L 移植瘤模型中抑制PARP，从而增强temozolomide的抗癌活性。^[1]ABT-888和其他细胞毒素药剂联用作用于MX-1移植瘤模型时显示出强抗癌效力。^[2]在A375和 Colo829移植瘤模型中按肿瘤大小，每千克分别加3和12.5 mg ABT-888，可以看到肿瘤内95%以上PAR被抑制。^[4]

激酶实验：^[1]	- 合并体外PARP实验: 在含有50 mM Tris (pH 为8.0), 1 mM DTT,和 4 mM MgCl₂的缓冲溶液中进行酶活性测定。PARP反应包含1.5 μM [³H]-NAD⁺ (1.6 μCi/mmol), 200 nM 生物素组蛋白 H1, 200 nM slDNA,及1 nM PARP-1或4 nM PARP-2酶。在加有100 μL 反应液的 96孔板上进行SPA检测。在50 μL含有PARP和DNA的2×酶液混合物中加入50 μL 2×NAD⁺基底混合物，反应开始。加入150 μL 1.5 mM 苯甲酰胺反应停止。170uL反应终止液转移到链霉亲和素包被的闪熔镀层上，温育1小时，用微型板块闪烁计数器计数。
细胞实验：^[2]	- 合并 Cell lines: C41细胞 Concentrations: 10 μM 左右 Incubation Time: 0.5小时 Method: 在96孔板上用ABT-888处理C41细胞0.5小时。用1 mM H₂O₂破坏DNA10分钟，PARP被激活。用冰冻的PBS冲洗细胞，然后用预冷的甲醇/丙酮（按7:3比例混合）在−20^oC下固定10 分钟。风干后，用PBS再溶解，然后用溶有5%脱脂奶粉的PBS- Tween封闭液(0.05%)在室温下阻断0.5小时。细胞和PAR抗体按1：50比例在封闭液中室温下温育1小时，然后用PBS-Tween-20冲洗5分钟，然后加入荧光素-5(6)-异硫氰酸酯 (FITC)-联用的二抗和1μg/mL DAPI封闭液中室温下温育1小时。PBS-Tween-20冲洗5分钟后，用荧光微型版计数器分析数据。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带NCI-H460, H460, B16F10和9L移植瘤的C57BL/6鼠 Dosages: 25或3.125 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

[4] Kinders RJ, et al, Clin Cancer Res, 2008, 14(21), 6877-6885.

- 合并

溶解度 (25°C)

体外	DMSO	17 mg/mL (69.58 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 0.5% methylcellulose+0.2% Tween 80	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Veliparib (ABT-888) SDF

分子量	244.29
化学式	C₁₃H₁₆N₄O
CAS号	912444-00-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NSC 737664

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03044795	Withdrawn	Drug: Veliparib	Cancer	University Medical Center Groningen\|AbbVie\|Dutch Cancer Society	November 2019	Phase 2
NCT02723864	Active not recruiting	Drug: Veliparib + VX-970 + Cisplatin	Neoplasms	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	August 9 2017	Phase 1
NCT02483104	Completed	Drug: veliparib\|Drug: carboplatin\|Drug: paclitaxel	Ovarian Cancer	AbbVie	July 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

选择性强的PARP抑制剂

AG-14361 : PARP1-selective, K_i<5 nM.
活性最高的PARP抑制剂

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
用于临床的PARP抑制剂

Iniparib (BSI-201) : Phase III for solid tumors.
最新的PARP抑制剂

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

研究领域

产品类型

定制您的化合物库

Veliparib (ABT-888)

客户使用Selleck生产的Veliparib (ABT-888)发表文献189篇：

产品安全说明书

PARP抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Veliparib (ABT-888) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品